These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

840 related items for PubMed ID: 19716456

  • 1. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
    King JC, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P.
    Vaccine; 2009 Nov 05; 27(47):6589-94. PubMed ID: 19716456
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
    Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM.
    Vaccine; 2011 Mar 09; 29(12):2272-8. PubMed ID: 21277410
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.
    Pediatr Infect Dis J; 2012 May 09; 31(5):494-500. PubMed ID: 22301476
    [Abstract] [Full Text] [Related]

  • 4. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
    Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, Romaguera JE, Goy AH, Hagemeister FB, McLaughlin P, Bodey GP, Kwak LW, Raad II, Couch RB.
    J Infect Dis; 2006 Nov 15; 194(10):1394-7. PubMed ID: 17054068
    [Abstract] [Full Text] [Related]

  • 5. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 15; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 6. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
    Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, Wolff M, She D, Cox MM.
    J Infect Dis; 2006 May 01; 193(9):1223-8. PubMed ID: 16586358
    [Abstract] [Full Text] [Related]

  • 7. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity.
    Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ.
    J Infect Dis; 2009 Sep 15; 200(6):849-57. PubMed ID: 19673652
    [Abstract] [Full Text] [Related]

  • 8. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 15; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
    Avila Aguero ML, Soriano-Fallas A, Umaña-Sauma MA, Ulloa-Gutierrez R, Arnoux S.
    Medicina (B Aires); 2007 Sep 15; 67(4):351-9. PubMed ID: 17891930
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D.
    J Infect Dis; 2006 Oct 15; 194(8):1032-9. PubMed ID: 16991077
    [Abstract] [Full Text] [Related]

  • 11. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA, Walter E, Black S, Blatter M, Nyberg J, Ruben FL, Decker MD, GRC28 Study Team.
    Pediatr Infect Dis J; 2010 Feb 15; 29(2):105-10. PubMed ID: 19934787
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J, Garcés-Sanchez M, Baldó JM, Planelles MV, Ubeda I, JuBert A, Marés J, Moris P, Garcia-Corbeira P, Dramé M, Gillard P.
    Pediatr Infect Dis J; 2010 Jun 15; 29(6):e35-46. PubMed ID: 20375709
    [Abstract] [Full Text] [Related]

  • 13. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
    Plennevaux E, Blatter M, Cornish MJ, Go K, Kirby D, Wali M, Reeves-Hoché MK, Denis M.
    Vaccine; 2011 Feb 11; 29(8):1569-75. PubMed ID: 21219979
    [Abstract] [Full Text] [Related]

  • 14. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.
    Vaccine; 2007 May 10; 25(19):3871-8. PubMed ID: 17337102
    [Abstract] [Full Text] [Related]

  • 15. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951
    [Abstract] [Full Text] [Related]

  • 16. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD, CAIV-T Study Group.
    Pediatr Infect Dis J; 2006 Oct 27; 25(10):870-9. PubMed ID: 17006279
    [Abstract] [Full Text] [Related]

  • 17. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.
    Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, Leroux-Roels G.
    Vaccine; 2008 Dec 02; 26(51):6614-9. PubMed ID: 18930093
    [Abstract] [Full Text] [Related]

  • 18. FluBlok, a next generation influenza vaccine manufactured in insect cells.
    Cox MM, Hollister JR.
    Biologicals; 2009 Jun 02; 37(3):182-9. PubMed ID: 19297194
    [Abstract] [Full Text] [Related]

  • 19. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children.
    Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM.
    Pediatrics; 2005 Apr 02; 115(4):1039-47. PubMed ID: 15805382
    [Abstract] [Full Text] [Related]

  • 20. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old.
    Keitel WA, Treanor JJ, El Sahly HM, Gilbert A, Meyer AL, Patriarca PA, Cox MM.
    Vaccine; 2009 Dec 11; 28(2):379-85. PubMed ID: 19879222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.